1. Scrip
  2. >>Therapy Areas

FDA OK's 1st generic copycats of Otsuka's Abilify

 
• By Donna Young

Otsuka was unsuccessful in preventing the FDA from approving generic versions of the company's schizophrenia and bipolar disorder drug Abilify (aripiprazole).

Otsuka was unsuccessful in preventing the FDA from approving generic versions of the company's schizophrenia and bipolar disorder drug Abilify (aripiprazole).

The agency gave the go-ahead on 28 April to Alembic Pharmaceuticals, Hetero Labs, Teva and Torrent Pharmaceuticals to market generic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.